Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Twelve co-development deals closed between March 15 and September 15, 2026 — up from exactly zero in the prior six-month period. That's a 1200% increase, and it isn't a statistical anomaly. It's the sharpest acceleration in co-dev deal trends in at least three years, driven by Big Pharma's simultaneous need to de-risk late-stage assets and accelerate commercial reach in overlapping therapeutic areas. The co-dev licensing 2026 wave is rewriting how risk, costs, and upside get split between partners.

The Data — Co-Dev Deal Activity, Period over Period

The baseline of zero isn't because co-development didn't exist before Q4 2025. It existed — but largely as informal arrangements buried inside broader licensing agreements. What changed is the emergence of standalone, structurally distinct co-development frameworks where two companies share IND ownership, split clinical trial costs at defined ratios, and negotiate territory-based profit splits rather than milestone-and-royalty waterfalls. When you filter for that deal architecture, the prior period was a desert. Now it's the fastest-growing deal type tracked on Deal Benchmarks.

What's Driving the Trend

Pipeline concentration risk is the primary accelerant. Seven of the top 15 pharma companies by market cap face patent cliffs between 2027 and 2030 on assets generating over $5B in annual revenue. The traditional response — acquire or in-license a replacement — has become prohibitively expensive. Median upfront payments for Phase 2+ oncology assets hit $250M in H1 2026 according to DealForma data. Co-development offers a structural alternative: share the Phase 3 costs (which routinely exceed $500M for registrational oncology trials), share the regulatory risk, and split the commercial economics rather than paying a massive upfront premium on assets with binary clinical outcomes.

Regulatory complexity is making solo development harder. FDA's evolving requirements around combination endpoint trials, real-world evidence integration, and post-market commitments have increased the operational burden of late-stage programs. Two companies co-developing an asset can divide regulatory workstreams — one handles US filing strategy while the other manages EMA and PMDA submissions. This isn't theoretical. AstraZeneca's co-dev arrangement with Merck, announced July 20, 2026, explicitly assigns regulatory lead responsibilities by geography, a structure that would have been unusual even 18 months ago.

Capital discipline is a board-level mandate. Biotech funding rounds in H1 2026 were down 18% in aggregate dollars versus H1 2025, per Evaluate Pharma. Even cash-rich large pharma companies are under investor pressure to improve ROIC on R&D spending. Co-development is the capital-efficient middle ground between full acquisition (high upfront, full risk) and traditional licensing (limited control, capped upside). It lets both parties keep skin in the game without either one writing a $2B check on a coin flip.

Notable Deals

The AstraZeneca-Merck co-development deal is the marquee transaction. These are two companies that historically preferred to own assets outright. The fact that they've structured a shared-ownership development framework — rather than AZ licensing to Merck or vice versa — signals a philosophical shift at the C-suite level: the risk on late-stage assets has become too large and too binary for even a $200B+ market cap company to underwrite alone.

The AbbVie-Janssen dynamic is equally telling. Two deals closed within 48 hours involving these parties, with Pharmacyclics/AbbVie licensing to Janssen and Janssen (J&J) licensing to AbbVie on a separate asset. This is a reciprocal co-development relationship — each company contributing pipeline assets to a shared development ecosystem. It's closer to a joint venture than a licensing deal, and it suggests we'll see more bilateral co-dev frameworks where large pharma companies essentially pool complementary assets rather than competing on overlapping programs.

Amgen's two co-dev deals — with BeiGene and Novartis, both on the same date — point to a deliberate portfolio strategy. Amgen appears to be using co-development selectively to extend geographic reach (BeiGene's China infrastructure) and therapeutic depth (Novartis's capabilities in specific modalities) without ceding full ownership. This is the playbook other companies will replicate.

What This Means for BD Teams Right Now

If you're selling, co-development is your leverage play. Offering a co-dev structure instead of a straight out-license lets you retain upside while still accessing your partner's capital and capabilities. In a market where upfront payments on traditional licenses are under pressure — median upfronts for Phase 2 assets dropped 12% sequentially in H1 2026 — co-dev terms can preserve total deal economics while reducing the buyer's sticker shock. Use Solidus to model how a 50/50 cost-sharing arrangement compares to a royalty-heavy license on a risk-adjusted NPV basis. The math often favors the co-dev structure for the asset owner.

If you're buying, move now but structure carefully. The window for co-development partnerships at reasonable economics is narrowing. As more companies adopt this framework, competition for co-dev-ready assets will increase, and the profit-sharing terms will shift toward the licensor. BD teams should be proactive about identifying Phase 2 assets where a co-development pitch — rather than a traditional term sheet — gives them a structural advantage in a competitive process. The companies that showed up with co-dev proposals in Q2 2026 won deals that the traditional licensors didn't even get to bid on.

Deal structures are evolving. The emerging standard in co-dev licensing 2026 is a tiered cost-sharing model: 60/40 or 70/30 cost splits during Phase 2, shifting to 50/50 in Phase 3, with profit splits calibrated to each party's cost contribution plus a premium for the originator's IP. Milestone payments are declining in importance — replaced by shared governance committees with decision rights tied to cost share. If your term sheets still lead with milestones and royalties, you're negotiating with last year's playbook.

Benchmark your deal against current market rates using the Ambrosia calculator. Co-dev deal structures are moving fast — the terms that were aggressive in Q1 are table stakes by Q3. Know where you stand before you sit down at the table.